Chon, Y.E., Park, J.Y., Myoung, S.-M., Jung, K.S., et al. (2017) Improvement of Liver Fibrosis after Long-Term Antiviral Therapy Assessed by Fibroscan in Chronic Hepatitis B Patients with Advanced Fibrosis. The American Journal of Gastroenterology, 112, 882-891.
https://doi.org/10.1038/ajg.2017.93

has been cited by the following article:

• TITLE: Diagnostic Efficacy of Serum Factor IV Collagen of Hepatic Fibrosis Regression in Chronic Hepatitis B Virus Infected Patients

  AUTHORS: Ali A. Ghweil, Heba A. Osman, Ashraf Khodeary

  KEYWORDS: Entecavir, Hepatic Fibrosis, HBV

  JOURNAL NAME: Advances in Infectious Diseases, Vol.8 No.4, November 19, 2018

  ABSTRACT: Purpose: Chronic hepatitis B virus infection affects more than 3 million people worldwide. The present study aimed to evaluate the role of pretreatment factor IV collagen as predictor of post treatment virological response with hepatic fibrosis regression. Materials and Methods: This prospective cohort study has been conducted on 74 naieve patients with chronic HBV infection with variable degree of hepatic fibrosis (F2, F3, ≥F4), viral load, and variable degree of abnormality in laboratory parameters of liver functions. All patients treated with Entecavir 0.5 mg/day or 1 mg/day according to severity of hepatic condition for 1 year. Liver fibrosis assessed using fibroscan, factor IV collagen, (APRI) and (FIB-4) scores evaluation. Results: All included patients in our study achieve post treatment Virological response with undetectable HBV DNA PCR ( Conclusion: Low pretreatment factor IV collagen is significantly correlated with virologial response and hepatic fibrosis regression post Entecavir therapy in patients with chronic HBV infection.